• Combined incidence of the number of patients with at least 1 reported CRAE and the combined incidence of the number of patients with specific reported CRAEs summarized according to the categories listed above [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
• Rate of supplemental analgesia consumed [ Time Frame: Days 1-10 ] [ Designated as safety issue: No ]
• Vital signs [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
• Summed Pain Intensity (SPI) of sternotomy alone and overall body pain over 8 hours (SPI 8) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
• Opioid-related Symptoms Distress Scale (OR-SDS) [ Time Frame: Days 1-10 ] [ Designated as safety issue: No ]
• Time to last Patient Controlled Analgesia (PCA) dose [ Designated as safety issue: No ]
• Recovery measures (length of stay, intensive care unit/hospital recovery and eligibility for discharge) [ Designated as safety issue: No ]
• Combined incidence of the number of patients with specific confirmed CRAEs in categories of cardiovascular thromboembolic CRAEs, renal CRAEs, upper gastrointestinal ulcer CRAEs, and wound healing complication CRAEs [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
• Adverse events [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
• Serious adverse events [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
• Clinical laboratory assessments [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
• Peak Pain Intensity (PPI) of sternotomy alone and overall body pain [ Time Frame: Days 1-10 ] [ Designated as safety issue: No ]
• Patient's and Physician's Global Evaluation of Study Medication [ Time Frame: At time of transition from intravenous to oral medication and final visit/early termination ] [ Designated as safety issue: No ]
• Modified Brief Pain Inventory-short form (mBPI-sf) [ Time Frame: Days 1-10 ] [ Designated as safety issue: No ]
• SPI of sternotomy alone and overall body pain over 12 hours (SPI 12) and 24 hours (SPI 24) [ Time Frame: Days 1-10 ] [ Designated as safety issue: No ]

The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery

• Drug: Parecoxib Sodium/Valdecoxib
• Drug: Placebo/Valdecoxib
• Other: Placebo/Placebo

Inclusion criteria:

• Patients expected to receive in-hospital pain medication for pain after coronary artery bypass graft surgery for at least 3 full days and pain medication over a 10-day period
• New York Heart Association Class I to III or cardiac ejection fraction of at least 35% before surgery
• Body mass index of less than or equal to 40 kg/m2 and weight of >55 kg
• Patients scheduled to undergo an isolated (bypass grafting only without valve replacement, significant aortic reconstruction, or ventriculoplasty) primary CABG surgery via median sternotomy, using cardiopulmonary bypass

Exclusion criteria:

• Patient has undergone or is going to have emergency coronary artery bypass graft surgery or surgery without cardiopulmonary bypass procedure
• Symptomatic peripheral vascular disease
• Heart attack within 48 hours of surgery